Novel therapeutic agents containing secretome derived from mesenchymal stem cells of umbilical cord tissue or Wharton's jelly
A secretome derived from mesenchymal stem cells addresses the challenges of chronic wounds by promoting cell proliferation and metabolism, resulting in enhanced wound healing through specific cytokines and growth factors.
Patent Information
- Application Number
- JP2024532815
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-03-04
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-15
AI Technical Summary
Chronic wounds and difficult-to-heal wounds face complications due to bacterial infections and impaired healing processes, posing a significant burden on healthcare systems and requiring effective therapeutic agents to promote acute wound response.
A therapeutic agent comprising a secretome derived from mesenchymal stem cells of umbilical cord tissue or Wharton's jelly, containing specific cytokines and growth factors, is developed to activate signaling pathways in epithelial and non-epithelial cells.
The secretome promotes wound healing by enhancing cell proliferation, metabolism, angiogenesis, and matrix deposition, leading to faster wound closure and improved healing outcomes.
Smart Images

Figure 2024542750000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to novel therapeutic agents and formulations or pharmaceutical compositions containing such therapeutic agents; ideally, but not exclusively, for use in the treatment of wounds; methods of making said therapeutic agents; and methods of treating wounds using said therapeutic agents. [Background technology]
[0002] Wounds are usually tears, cuts or holes in the skin (open wounds) or wounds resulting from blunt trauma causing contusions (closed wounds). In either case, the epidermis of the skin is broken.
[0003] Wounds can be classified as follows: clean wounds - created under sterile conditions, free of microorganisms, the skin is likely to heal without complications; contaminated wounds - usually resulting from accidental injury and containing pathogenic microorganisms and foreign bodies within the wound; infected wounds - containing pathogenic microorganisms that multiply and show clinical signs of infection; and colonized wounds - which are chronic, contain pathogenic microorganisms, and are difficult to heal (e.g., pressure ulcers).
[0004] Additionally, wounds can be classified as open or closed.
[0005] Open wounds are classified according to the object that caused the wound: cut - caused by a clean, sharp object (e.g., a knife, razor, or broken glass); laceration - an irregular tear-like wound caused by any blunt trauma; abrasion - a superficial wound in which the top layer of skin (epidermis) has been scraped away; avulsion - a body structure is forcibly separated from its normal point of insertion; puncture wound - caused by an object (e.g., a thorn, nail, needle) that pierces the skin; penetration wound - caused by an object (e.g., a knife) penetrating the skin and emerging through it; gunshot wound - caused by a bullet or similar projectile piercing or penetrating the body; and severe burns - including severe lacerations.
[0006] Closed wounds are just as dangerous as open wounds, although there are fewer categories: hematomas (or blood tumors) - caused by damaged blood vessels that allow blood to collect under the skin; hematomas caused by internal vascular pathology are petechiae, purpura, and ecchymoses (which are classified differently based on size); hematomas caused by external trauma are contusions, also commonly called contusions; and crush injuries - caused by great or extreme force applied over a long period of time.
[0007] Complications such as bacterial wound infection can impede the healing process and lead to life-threatening complications. Therefore, it is important to ensure that wounds heal quickly and effectively. Furthermore, if wounds do not heal quickly, the cost of wound care to the health care system becomes a huge burden on facilities.
[0008] The term "chronic wound" refers to wounds that arise in patients with physiological healing disorders that tend to cause skin wounds to deviate from the characteristics of acute wound healing.
[0009] An estimated 3-6 million patients develop chronic skin ulcers each year in the United States. The most common underlying conditions are venous reflux, pressure, and diabetes. Summary of the Invention [Problem to be solved by the invention]
[0010] All wounds, especially those that are difficult to heal, are candidates for wound healing therapies that enhance the acute wound response; thus, compensating for missing or dysfunctional components present in chronic wounds.
[0011] The invention described herein relates particularly, but not exclusively, to a novel therapeutic approach for use in wound healing, particularly chronic wounds, which acts to activate signaling pathways in both epithelial and non-epithelial cells and involves a myriad of different cytokines and growth factors, thus resulting in a relatively complex but effective therapeutic approach. [Means for solving the problem]
[0012] According to a first aspect of the present invention, there is provided a therapeutic agent comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or mesenchymal stem cells of Wharton's jelly tissue.
[0013] Wharton's jelly, as referred to herein, is a gel-like substance within the umbilical cord that is composed mostly of mucopolysaccharides (hyaluronic acid and chondroitin sulfate), functions as a mucous connective tissue that contains some fibroblasts and macrophages, and is derived from the extraembryonic mesoderm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] In a preferred embodiment of the invention, the secretome comprises or consists of the following components: granulocyte colony stimulating factor (G-CSF); growth regulatory protein alpha (GRO-a); hepatocyte growth factor (HGF); interleukin-6 (IL-6); leukemia inhibitory factor (LIF); monocyte chemotactic protein 3 (MCP-3); stem cell growth factor beta (SCGF-b); tissue inhibitor of metalloproteinase 1 (TIMP-1); matrix metalloproteinase 3 (MMP-3); angiopoietin-like protein 4 (ANGPTL4), tumor necrosis factor receptor RI (TNF-RI), and CD63+ exosomes.
[0015] In a further preferred embodiment of the invention, the secretome further comprises or consists of at least one of the following components (including any combination thereof): interleukin-8 (IL-8); monocyte chemotactic protein 1 (MCP-1); macrophage migration inhibitory factor (MIF); tissue inhibitor of metalloproteinase 2 (TIMP-2); angiopoietin-1; follistatin; matrix metalloproteinase 1 (MMP-1); matrix metalloproteinase 2 (MMP-2); and matrix metalloproteinase 8 (MMP-8).
[0016] In a further preferred embodiment of the invention, the components are present in the following relative amounts: [Table 1]
[0017] References to relative amounts herein are to the amount of each component taking into account a reference component (i.e., granulocyte-colony stimulating factor (G-CSF)) which is designated as 1.0 at a concentration of 22166 pg / mL, and therefore the amount (pg / mL) of each other component is divided by 22166 to derive the relative amount.
[0018] In further preferred embodiments, the ingredients are present in the following amounts: [Table 2]
[0019] In a further preferred embodiment, the therapeutic agent comprises CD63+ exosomes in an amount of about 2-30 μg / mL, ideally 5-20 μg / mL.
[0020] In yet another embodiment of the invention, the components are present in any of the relative amounts or concentration amounts set forth above.
[0021] Reference herein to CD63 is a reference to the antigen, which is a protein and, in humans, is encoded by the CD63 gene. CD63 is primarily associated with the membrane of intracellular vesicles.
[0022] According to a further aspect of the present invention there is provided a method of producing a therapeutic comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or mesenchymal stem cells of Wharton's jelly tissue, the method comprising: 1. Cultivating umbilical cord mesenchymal stem cells or Wharton's jelly mesenchymal stem cells until confluent; 2. Removing the growth medium and washing the cell layer with an isotonic salt solution; 3. Incubating the cells in a medium that does not contain growth factors; then 4. Incubating the cells in a growth factor medium; and 5. Recovering a cellular secretome from said cell; Contains:
[0023] In a preferred method of the present invention, step 3 and / or step 4 may be repeated one or more times, and step 5 may be performed after step 3 and / or step 4.
[0024] In a further preferred method, steps 3 and 4 may be reversed such that incubation in growth factor medium precedes incubation in growth factor-free medium.
[0025] In the above method, preferably, the isotonic salt solution is phosphate buffered saline. This step is carried out to remove growth medium components.
[0026] In the above-mentioned method, preferably, the medium not containing the growth factor contains a basal medium (e.g., DMEM) containing 0.01 to 0.5% human serum albumin or recombinant human serum albumin, 50 to 500 μM sodium ascorbyl phosphate, and pen-strep-glutamax-NEAA.
[0027] In the above-mentioned method, preferably, the growth factor medium comprises a basal medium (e.g., DMEM) containing 0.1 to 2 IU of FGF2 and / or EGF and / or TGFβ and / or PDGF, 0.01 to 0.5% human serum albumin or recombinant human serum albumin, 50 to 500 μM sodium ascorbyl phosphate and pen-strep-glutamax-NEAA.
[0028] In the above method, steps 3-6 can be repeated multiple cycles. Ideally, in total, the cells are cultured / incubated for 2-14 days.
[0029] In a further preferred method of the present invention, the collected secretomes are sterile filtered and concentrated by ultrafiltration, and the concentrated secretomes are pooled to provide the final secretomes for use in downstream applications.
[0030] More preferably, the secretome is stabilized by adding 0.1-1% carrier protein and / or 0.5-10 mM sodium ascorbyl phosphate and / or 0.5-20% sucrose and / or phosphate buffer.
[0031] The secretome can also be frozen or lyophilized for long-term storage.
[0032] According to a further aspect of the present invention, there is provided a novel therapeutic agent comprising the secretome obtained by the above method.
[0033] According to yet another aspect of the invention there is provided a method of treating a wound, the method comprising administering to the wound said therapeutic agent.
[0034] According to a further aspect of the invention there is provided a therapeutic agent of the invention (which may be produced or obtained using the method of the invention) for use in treating wounds.
[0035] According to a further aspect of the invention there is provided the use of a therapeutic agent of the invention (which may be produced or obtained using a method of the invention) in the manufacture of a medicament for treating a wound.
[0036] In the claims which follow and in the preceding description of the invention, unless the context requires otherwise, either by express expression or necessary implication, the word "comprise" or variations thereof, such as "comprises" or "comprising", is used in its inclusive sense, i.e., to specify the presence of stated features, but is not used to exclude the presence or addition of further features in various embodiments of the invention.
[0037] All references cited herein, including any patents or patent applications, are hereby incorporated by reference. No admission is made that any reference constitutes prior art. Further, no admission is made that any prior art constitutes part of the general knowledge in the art.
[0038] Preferred features of each aspect of the invention may be as described in relation to any of the other aspects.
[0039] Other features of the present invention will become apparent from the following examples. Generally speaking, the present invention covers any novel one or any novel combination of features disclosed in this specification (including the accompanying claims and drawings). Thus, it should be understood that a feature, integer, property, compound or chemical moiety described in connection with a particular aspect, embodiment or example of the present invention is also applicable to any other aspect, embodiment or example described herein, unless inconsistent therewith.
[0040] Moreover, unless stated otherwise, any feature disclosed in this specification may be replaced by an alternative feature serving the same or a similar purpose.
[0041] Throughout the description and claims of this specification, the singular encompasses the plural, unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood to contemplate the plural as well as the singular, unless the context requires otherwise.
[0042] Embodiments of the invention will now be described, by way of example only, with reference to the following. [Brief description of the drawings]
[0043] [Figure 1A] The efficacy of the secretome on cell proliferation and metabolism is shown using human dermal fibroblasts, human keratinocytes and human endothelial cells. Cells were treated with assay diluent (untreated), unconditioned medium (control) or secretome for 3 (endothelial cells), 4 (keratinocytes) or 5 days (fibroblasts). Cell proliferation and metabolism are shown for human dermal fibroblasts (1A), human keratinocytes (1B) and human endothelial cells (1C). [Figure 1B] The efficacy of the secretome on cell proliferation and metabolism is shown using human dermal fibroblasts, human keratinocytes and human endothelial cells. Cells were treated with assay diluent (untreated), unconditioned medium (control) or secretome for 3 (endothelial cells), 4 (keratinocytes) or 5 days (fibroblasts). Cell proliferation and metabolism are shown for human dermal fibroblasts (1A), human keratinocytes (1B) and human endothelial cells (1C). [Figure 1C]The efficacy of the secretome on cell proliferation and metabolism is shown using human dermal fibroblasts, human keratinocytes and human endothelial cells. Cells were treated with assay diluent (untreated), unconditioned medium (control) or secretome for 3 (endothelial cells), 4 (keratinocytes) or 5 days (fibroblasts). Cell proliferation and metabolism are shown for human dermal fibroblasts (1A), human keratinocytes (1B) and human endothelial cells (1C). [Diagram 2] The efficacy of secretome on cell proliferation and metabolism is demonstrated using human dermal fibroblasts, human keratinocytes and human endothelial cells. Cells were treated with assay diluent (untreated), unconditioned medium (control) or secretome for 3 days (endothelial cells), 4 days (keratinocytes) or 5 days (fibroblasts). Cell proliferation is demonstrated by staining the cells with Safranin O. [Figure 3A] 3A shows the effect of secretome on wound healing. Wounds equivalent to de-epidermised human skin were left untreated or treated with un-conditioned medium (control) or secretome for 3 days. On day 7, wound closure was assessed visually by MTT staining (3A) and quantitatively using the images from FIG. 3A (3B). [Figure 3B] 3A shows the effect of secretome on wound healing. Wounds equivalent to de-epidermised human skin were left untreated or treated with un-conditioned medium (control) or secretome for 3 days. On day 7, wound closure was assessed visually by MTT staining (3A) and quantitatively using the images from FIG. 3A (3B). [Figure 4]Figure 1 shows the effect of secretome on wound healing. Wounds equivalent to de-epidermised human skin were left untreated or treated with un-conditioned medium (control) or secretome for 3 days. On day 7, wound closure was visually assessed by H&E staining after sectioning. The red vertical line indicates the initial wound edge on day 0. Secretome promotes keratinocyte proliferation and migration (faster wound bed closure) compared to control (P<0.05). Control (un-conditioned medium) showed no effect compared to untreated wounds (P>0.05). [Figure 5A] Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. [Figure 5B] Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. [Figure 5C] Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. [Figure 5D]Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. [Figure 5E] Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. [Figure 5F] Figure 5 shows the effect of secretome on wound healing in vivo. Rats were made with full thickness wounds. Wounds were left untreated (5A and 5D), treated with unconditioned medium (control 5B and 5E) or treated with secretome (5C and 5F) for 3 days. On days 3 (5A-C) and 5 (5D-F), wound closure and wound bed analysis were assessed by sectioning followed by H&E staining. EXAMPLES
[0044] Methods and Materials Stem cell secretome production 1. Culture Celligenics stem cells until they are 95-100% confluent.
[0045] 2. The growth medium is removed and the cell layer is washed twice with an isotonic salt solution (eg, phosphate buffered saline) to remove growth medium components.
[0046] 3. The cells are then incubated with a growth factor-free medium containing a basal medium (e.g., DMEM, etc.) containing 0.01-0.5% human serum albumin or recombinant human serum albumin, 50-500 μM sodium ascorbyl phosphate and pen-strep-glutamax-NEAA, or a growth factor medium containing a basal medium (e.g., DMEM) containing 0.1-2 IU of FGF2 and / or EGF and / or TGFβ and / or PDGF, 0.01-0.5% human serum albumin or recombinant human serum albumin, 50-500 μM sodium ascorbyl phosphate and pen-strep-glutamax-NEAA.
[0047] 4. After, for example, 2 days, harvest the medium (day 2 secretomes) and repeat step 3.
[0048] 5. Steps 3 and 4 can be repeated several cycles to harvest the secretome.
[0049] Processing after stem cell secretome production 1. The collected secretomes from above are sterile filtered and concentrated by ultrafiltration. The concentrated secretomes from multiple collection days are pooled to yield the final secretomes to be used in downstream applications.
[0050] 2. The secretome is stabilized prior to freezing or lyophilization by adding 0.1-1% carrier protein and / or 0.5-10 mM sodium ascorbyl phosphate and / or 0.5-20% sucrose and / or phosphate buffer.
[0051] Characterization of the stem cell secretome The collected secretome was analyzed and its active components included growth factors, cytokines, enzymes, signaling molecules, matrix proteins and extracellular vesicles. The amounts listed below are normalized and averaged relative to the amounts that would have been present in the secretome when originally collected. The secretome also contains CD63+ exosomes (approximately 2-30 μg / mL). [Table 3]
[0052] Using the secretome for wound healing In vitro: 2D cell-based assays Objectives and Methods: To evaluate the effect of the secretome on cell proliferation and metabolism. Human dermal fibroblasts, human keratinocytes and human endothelial cells were seeded in 96-well plates. Cells were treated with assay diluent (untreated), un-conditioned medium (control) or secretome for 5 days (fibroblasts), 4 days (keratinocytes) or 3 days (endothelial cells). Cell proliferation and metabolism were assessed by staining with CCK8 reagent followed by absorbance reading at 450 nm and comparison to cell standards. Evidence of cell proliferation was further demonstrated by staining cells with Safranin O.
[0053] In vitro: 3D skin model Objectives and Methods: To evaluate the effect of secretome on wound healing, de-epidermised human skin equivalents were prepared. Wounds were left untreated or treated with unconditioned medium (control) or secretome for 3 days. On day 7, wound closure was assessed by MTT staining or by H&E staining after sectioning.
[0054] In vivo: rat wound model Objectives and Methods: To evaluate the potential effect of secretome on wound healing, full-thickness wounds were created in rats. Wounds were left untreated or treated with unconditioned medium (control) or secretome for 3 days. On days 3 and 5, wound closure and wound bed analysis were assessed by H&E staining after sectioning.
[0055] result Applications of stem cell secretome The secretome was tested for wound healing properties in various assays: it promotes proliferation of dermal fibroblasts, keratinocytes and endothelial cells;
[0056] The secretome also promotes keratinocyte proliferation and differentiation in de-epidermised dermal human skin equivalents.
[0057] In animal models, the secretome promotes faster wound closure, angiogenesis and matrix deposition / maturation.
[0058] Figures 1 and 2 show that secretome promotes proliferation and metabolism of human dermal fibroblasts, keratinocytes and endothelial cells compared to the control (P<0.05). The control (un-conditioned medium) showed no effect on cells not treated with secretome (P>0.05). In Figure 2, the secretome-treated panel shows more proliferation, suggesting increased metabolism.
[0059] The effect of secretome on wound healing was evaluated using de-epidermised human skin equivalents. Figures 3 and 4 show the effect of secretome on wound healing.
[0060] In Figure 3 it can be seen that the use of secretome promotes wound closure. The control shows no effect.
[0061] In Figure 4, images of the wounds are shown. The red vertical lines indicate the initial wound edge on day 0 for each wound. The wounds treated with secretome are closed, with the stratum corneum and stratum basale filling the wound. It can therefore be seen that secretome promoted keratinocyte proliferation and migration (faster wound bed closure) compared to the control (P<0.05). The control (un-conditioned medium) shows no effect on wounds not treated with secretome (P>0.05). Secretome promotes keratinocyte differentiation (stratification of the epidermis).
[0062] Figure 5 illustrates wound healing in a rat model on days 3 and 5 after treatment with control or secretome. Yellow dots depict epithelial tongues and black arrows indicate blood vessel formation. Secretome promotes re-epithelialization, angiogenesis, and extracellular matrix maturation compared to no treatment or treatment with un-conditioned medium.
[0063] Taken together, the data clearly demonstrate the regenerative effects of the secretome that can be advantageously used to treat wounds. [Table 4]
Claims
1. A therapeutic agent comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or mesenchymal stem cells of Wharton's jelly tissue, said secretome comprising or consisting of the following components: granulocyte colony stimulating factor (G-CSF); growth regulatory protein alpha (GRO-a); hepatocyte growth factor (HGF); interleukin-6 (IL-6); leukemia inhibitory factor (LIF); monocyte chemotactic protein 3 (MCP-3); stem cell growth factor beta (SCGF-b); tissue inhibitor of metalloproteinase 1 (TIMP-1); matrix metalloproteinase 3 (MMP-3); angiopoietin-like protein 4 (ANGPTL4), tumor necrosis factor receptor RI (TNF-RI), and CD63+ exosomes.
2. The therapeutic agent of claim 1, wherein the secretome comprises or consists of at least one of the following components (including any combination thereof): interleukin-8 (IL-8); monocyte chemotactic protein 1 (MCP-1); macrophage migration inhibitory factor (MIF); tissue inhibitor of metalloproteinase 2 (TIMP-2); angiopoietin-1; follistatin; matrix metalloproteinase 1 (MMP-1); matrix metalloproteinase 2 (MMP-2); and matrix metalloproteinase 8 (MMP-8).
3. The therapeutic agent according to claim 1 or 2, wherein the secretome comprises or consists of the following relative amounts of said components to the amount of G-CSF: 【Table 1】
4. The therapeutic agent according to any one of claims 1 to 3, wherein the secretome comprises or consists of the following amounts of the components: 【Table 2】
5. 5. The therapeutic agent of claim 4, wherein the amount of each component is present in the following amounts: 【Table 3】
6. The method of any one of the preceding claims, wherein the CD63+ exosomes are present in an amount of 2-30 μg / mL or 5-20 μg / mL.
7. 1. A method for producing a therapeutic agent comprising a secretome obtained from mesenchymal stem cells of umbilical cord tissue or mesenchymal stem cells of Wharton's jelly tissue, comprising: (i) culturing umbilical cord mesenchymal stem cells or Wharton's jelly mesenchymal stem cells until confluent; (ii) removing the growth medium and washing the cell layer with an isotonic salt solution; (iii) incubating the cells in a medium that does not contain growth factors; and then (iv) incubating the cells in a growth factor medium; and (v) recovering a cellular secretome from the cell; The method comprising:
8. 8. The method of claim 7, wherein step (iii) and / or step (iv) can be repeated one or more times and / or step (v) can be performed after step (iii) and / or step (iv).
9. 9. The method of claim 7 or claim 8, wherein steps (iii) and (iv) may be reversed such that incubation in growth factor medium precedes incubation in growth factor-free medium.
10. The method according to any one of claims 7 to 9, wherein said isotonic salt solution is phosphate buffered saline.
11. The method according to any one of claims 7 to 10, wherein the growth factor-free medium comprises a basal medium (e.g., DMEM) containing 0.01 to 0.5% human serum albumin or recombinant human serum albumin, 50 to 500 μM sodium ascorbyl phosphate and pen-strep-glutamax-NEAA.
12. 12. The method of any one of claims 7 to 11, wherein the growth factor medium comprises a basal medium (e.g., DMEM) containing 0.1-2 IU of FGF2 and / or EGF and / or TGFβ and / or PDGF, 0.01-0.5% human serum albumin or recombinant human serum albumin, 50-500 μM sodium ascorbyl phosphate and pen-strep-glutamax-NEAA.
13. 13. The method according to any one of claims 7 to 12, wherein the secretome is stabilized by adding 0.1-1% carrier protein and / or 0.5-10 mM sodium ascorbyl phosphate and / or 0.5-20% sucrose and / or phosphate buffer.
14. A therapeutic agent comprising a secretome obtained by the method according to any one of claims 7 to 13.
15. A therapeutic agent according to any one of claims 1 to 7, obtained by a method according to any one of claims 7 to 13.
16. A method of treating a wound, comprising administering to the wound a therapeutic agent according to any one of claims 1 to 6 or 14 or 15.
17. A therapeutic agent according to any one of claims 1 to 6, optionally produced or obtained by a method according to any one of claims 7 to 13 or 14 or 15, for use in wound treatment.
18. 16. Use of a therapeutic agent according to any one of claims 1 to 6, optionally produced or obtained using a method according to any one of claims 7 to 13 or 14 or 15, in the manufacture of a medicament for the treatment of wounds.
Citation Information
Patent Citations
Stem cell conditioned media for clinical and cosmetic applications
US20200230172A1
